Rifampicin-resistant pulmonary tuberculosis patient screening and treatment in Inner Mongolia, 2015–2020

  Objective  To understand the screening and treatment of rifampicin-resistant pulmonary tuberculosis (TB) patients in Inner Mongolia autonomous region from 2015 to 2020 and provide evidence for the development of local drug-resistant TB prevention and treatment strategies.

  Methods  The medical records of TB patients and the data of rifampicin resistant pulmonary TB patient screening and treatment in Inner Mongolia from 2015 to 2020 were collected from “Tuberculosis Information Management System”, the rate and composition ratio were used for descriptive statistical analysis.

  Results  The screening rate of rifampicin resistance was 60.7% in new pathogenic positive pulmonary TB patients and 72.2% in high-risk group in Inner Mongolia during 2015–2020, and the rifampicin resistance screening rates increased year by year (trend χ²=36625, P<0.0001; trend χ²=6465, P<0.0001); The detection rate of rifampicin resistance in pulmonary TB patients with different registration classification was 9.7%. The detection rate in new pathogenic positive pulmonary TB patients was 6.0%, and the detection rate in high-risk group was 22.3%, higher than that in new pathogenic positive pulmonary TB patients (trend χ²=13293, P<0.0001). The detection rate was highest in the patients with failed treatment (50.0%); The rate of treatment of rifampicin-resistant patients was 66.1% in new pathogenic positive pulmonary TB patients and 70.9% in high-risk group, and the annual rate increased year by year (trend χ²=928, P<0.0001, trend χ²=1095, P<0.0001).

  Conclusion  The rate of rifampicin resistance screening and the rate of treatment in pathogenic positive  pulmonary TB patients in Inner Mongolia increased year by year.